Bio-Path (BPTH) Competitors $0.97 -0.01 (-1.02%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BPTH vs. SNOA, SNTI, BCLI, JAGX, NKGN, CDT, ATHE, SNGX, UPXI, and RNAZShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Sonoma Pharmaceuticals (SNOA), Senti Biosciences (SNTI), Brainstorm Cell Therapeutics (BCLI), Jaguar Health (JAGX), NKGen Biotech (NKGN), Conduit Pharmaceuticals (CDT), Alterity Therapeutics (ATHE), Soligenix (SNGX), Upexi (UPXI), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Sonoma Pharmaceuticals Senti Biosciences Brainstorm Cell Therapeutics Jaguar Health NKGen Biotech Conduit Pharmaceuticals Alterity Therapeutics Soligenix Upexi TransCode Therapeutics Bio-Path (NASDAQ:BPTH) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends. Which has more risk and volatility, BPTH or SNOA? Bio-Path has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Do insiders and institutionals hold more shares of BPTH or SNOA? 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 3.1% of Bio-Path shares are held by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, BPTH or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ASonoma Pharmaceuticals$12.73M0.21-$4.84M-$10.20-0.27 Does the media prefer BPTH or SNOA? In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score. Company Overall Sentiment Bio-Path Neutral Sonoma Pharmaceuticals Neutral Do analysts prefer BPTH or SNOA? Bio-Path currently has a consensus target price of $20.00, suggesting a potential upside of 1,955.50%. Given Bio-Path's higher possible upside, analysts plainly believe Bio-Path is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is BPTH or SNOA more profitable? Bio-Path has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -35.91%. Sonoma Pharmaceuticals' return on equity of -65.66% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -306.66% Sonoma Pharmaceuticals -35.91%-65.66%-27.20% Does the MarketBeat Community favor BPTH or SNOA? Bio-Path received 66 more outperform votes than Sonoma Pharmaceuticals when rated by MarketBeat users. However, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 54.86% of users gave Bio-Path an outperform vote. CompanyUnderperformOutperformBio-PathOutperform Votes28254.86% Underperform Votes23245.14% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% SummarySonoma Pharmaceuticals beats Bio-Path on 7 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.48M$6.74B$5.01B$8.40BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A11.81128.8716.66Price / SalesN/A269.971,718.3776.45Price / CashN/A46.0936.9133.53Price / Book1.375.304.595.18Net Income-$16.08M$150.82M$114.09M$223.67M7 Day Performance-9.91%-1.00%110.31%2.58%1 Month Performance11.71%15.26%124.28%8.66%1 Year Performance-92.21%36.69%154.64%28.23% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path1.611 of 5 stars$0.97-1.0%$20.00+1,955.5%-92.2%$2.48MN/A0.0010Gap UpSNOASonoma Pharmaceuticals0.6135 of 5 stars$2.79+4.1%N/A+1,379.3%$2.57M$12.73M-0.27180Upcoming EarningsSNTISenti Biosciences1.6116 of 5 stars$2.18+0.5%N/A-24.3%$9.98M$2.56M-0.174Upcoming EarningsNews CoverageGap UpBCLIBrainstorm Cell Therapeutics3.8414 of 5 stars$1.86-0.5%$30.00+1,512.9%-29.8%$9.90MN/A-0.5440Upcoming EarningsJAGXJaguar Health0.9179 of 5 stars$1.06+1.0%N/A-94.6%$9.70M$9.76M0.0050Upcoming EarningsPositive NewsNKGNNKGen BiotechN/A$0.27-3.6%N/A-91.6%$9.45M$80,000.00-0.05N/AUpcoming EarningsGap DownCDTConduit PharmaceuticalsN/A$0.09flatN/A-92.2%$8.74MN/A0.003Gap UpATHEAlterity Therapeutics2.6589 of 5 stars$1.17+1.7%$4.00+241.9%-52.5%$8.40MN/A0.0010Positive NewsSNGXSoligenix0.2163 of 5 stars$3.86+5.2%N/A-52.5%$8.37M$840,000.00-0.4120Upcoming EarningsUPXIUpexi2.2768 of 5 stars$8.04+2.6%$25.00+210.9%-65.4%$8.36M$80.68M0.00130Gap DownRNAZTransCode Therapeutics2.2473 of 5 stars$0.48+2.1%$3.00+525.0%-96.4%$8.29MN/A0.009Upcoming Earnings Related Companies and Tools Related Companies SNOA Alternatives SNTI Alternatives BCLI Alternatives JAGX Alternatives NKGN Alternatives CDT Alternatives ATHE Alternatives SNGX Alternatives UPXI Alternatives RNAZ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BPTH) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTH Stock Alerts